Cover Image

IATROGENIC CUSHING'S SYDROME AND USE OF TOCILIZUMAB IN SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS - A CASE REPORT.

RINE BENSON T

Abstract


Cushing's syndrome refers to signs and symptoms caused by excess free plasma glucocorticoids. We report a case of iatrogenic Cushing's syndrome due to prolonged use of systemic steroids in systemic juvenile idiopathic arthritis and use of newer biologic tocilizumab as a treatment in systemic juvenile idiopathic arthritis.

 


Full Text:

PDF

References


Stratakis CA.Cushing syndrome in pediatrics. Endocrinology Metabolism Clinics of North America.2012;41:79.

Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.

Saag KG, Emkey R , Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.

Yokota S, Miyamae T, Imagawa T et al. Clinical Study of Tocilizumab in children with systemiconset juvenile idiopathic arthritis. Clin Rev Allergy Immunol.2005; 28:231-238.

Nelson, text book of pediatrics 20th edition.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr MGR Medical University